What's new? Log in Free sign up

Maze Therapeutics (MAZE)

Company Profile

Company profile

Ticker

MAZE

Exchange

Incorporated

Location

Fiscal year end

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • Gilead Sciences • Biogen • Qiagen • Sterling Check • Moderna • Bio-Techne • Acorda Therapeutics • Mach Natural Resources ...

SEC CIK

Corporate docs

Plans of Reorganization

Subsidiaries Lists

Latest filings (excl ownership)

Registration of additional securities for an S-1

Certification of approval for exchange listing

IPO registration (amended)

30 Jan 25

Registration of securities on exchange

IPO registration (amended)

27 Jan 25

IPO registration

Latest ownership filings

View all

Initial statement of insider ownership

DANIEL K SPIEGELMAN

Catherine A. Sohn

RICHARD H SCHELLER

Sekar Kathiresan

CHARLES J HOMCY

News

From Benzinga Pro

Reported Earlier, Maze Therapeutics Prices $140M Upsized Initial Public Offering Of 8.75M Common Shares At $16/Share

The shares are expected to begin trading on the Nasdaq Global Market on January 31, 2025, under the symbol "MAZE." The offering is expected to close on February 3, 2025, subject to the satisfaction of customary closing

Maze Therapeutics, Inc IPOs Tomorrow, Here's What You Need To Know

Press releases

From Benzinga Pro

Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.